Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
LONDON AND HONG KONG, Nov 10, 2022 - (ACN Newswire via SEAPRWire.com) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter ended September 30, 2022.Third Quarter 2022 and Recent Highlights:-- Reported third quarter 2022 revenue of US$80 million -- Reported loss from operations of US$9 million, adjusted earnings1 of US$21 million and adjusted EBITDA2 of US$27 million in the third quarter-- Achieved gross margin of 59% in the third quarter-- Appointed Professor Robert Harris, founder and former CEO of Lakeside Healthcare Group, one of UK's largest GP practices, as Executive Chairman of Prenetics EMEA-- Ended the third quarter with cash and other short-term assets3 of approximately US$250 million-- Obtained HSBC banking facilities of US$50 million for general corporate purposes and liquidity for potential acquisitions, demonstrating confidence from financial institutions Danny Yeung, Chief Executive Officer and Co-founder of Prenetics, said "I'm very proud of our strong results, demonstrating our continued growth, and reflecting the success we've...
